How Poor Sleep and Obesity Feed Each Other—and What New Drugs Change

Sleep and obesity are locked in a two-way relationship that scientists are only now beginning to untangle. A comprehensive review published in the Journal of Clinical Sleep Medicine by Christopher Schmickl, Atul Malhotra and colleagues at the University of California, San Diego synthesizes decades of evidence on how insufficient sleep, insomnia, obstructive sleep apnea and related disorders interact with excess body fat. Their central message is striking: the three pillars of health—diet, exercise and sleep—are so tightly interwoven that neglecting one undermines the other two, and effective weight management is becoming inseparable from modern sleep medicine.

The scale of the problem is enormous. More than 40 percent of adults in the United States now live with obesity, defined as a body mass index of 30 kg/m² or higher, with prevalence disproportionately high among certain racial, ethnic and socioeconomic groups. Obesity raises the risk of more than 200 diseases, from diabetes and heart disease to cancer, and is now formally recognized as a chronic disease in its own right. Crucially, the body’s energy homeostasis system actively defends an elevated fat mass “set point,” which means caloric restriction triggers persistent hunger while lowering energy expenditure. That biology explains why lifestyle programs alone typically produce only temporary, modest weight losses of 2 to 5 percent, and why weight regain after dieting is so common.

Insufficient sleep is the sleep problem most consistently linked to weight gain. Roughly one third of US adults sleep less than the recommended minimum of seven hours per night, and the hormonal consequences are well documented. In randomized studies conducted by Spiegel, Tasali and Van Cauter, sleep restriction lowered leptin, a satiety hormone, and raised ghrelin, an appetite stimulant—shifts that would predictably drive hunger. Sleep-deprived people also crave non-nutritious foods. Large epidemiological data reinforce the picture: in the Nurses’ Health Study, more than 68,000 women followed prospectively showed that those reporting five hours of sleep per night weighed more at baseline and gained more weight over time than those sleeping seven to eight hours, even after adjusting for known confounders.

Experimental trials add mechanistic weight to the association. In one study, participants restricted to four hours of sleep per night consumed an average of 308 additional kilocalories per day compared with controls given a nine-hour sleep opportunity, and they gained visceral fat—a depot closely tied to cardiometabolic risk. Sleep restriction also impaired the improvement in fat-free mass normally induced by dieting, meaning poor sleep can blunt the benefits of an otherwise sound diet. Encouragingly, the relationship runs in both directions: a recent real-world trial found that extending sleep by 1.2 hours reduced energy intake and produced a negative energy balance in adults who were habitually short sleepers. Sleep deprivation also impairs exercise performance, partly through inflammatory cytokines such as interleukin-6, compounding the metabolic damage.

Insomnia, by contrast, tells a surprisingly different story. Despite affecting more than 10 percent of US adults, insomnia shows only a weak and inconsistent relationship with obesity. A meta-analysis of predominantly cross-sectional studies found no significant association between an insomnia diagnosis and obesity status, and even analyses of insomnia symptoms and body mass index yielded only a tiny effect with very high heterogeneity. One hypothesis is that the physiological hyperarousal that defines insomnia may counteract obesity-promoting mechanisms. However, the picture is complicated by comorbid insomnia and sleep apnea, known as COMISA, a condition associated with greater symptom burden, poorer CPAP adherence and worse cardiometabolic outcomes than either disorder alone. Treating insomnia with cognitive behavioral therapy may improve acceptance of CPAP, suggesting that sequencing therapies matters.

Obstructive sleep apnea is where obesity exerts its strongest influence. Up to one billion people worldwide are estimated to have OSA, and roughly half of cases are attributable to excess body fat. The pathophysiology is multifaceted: fat deposited in the tongue and parapharyngeal tissues increases pharyngeal collapsibility, abdominal fat reduces end-expiratory lung volume and weakens the tethering that holds the upper airway open, and obesity can destabilize the chemical control of breathing by raising loop gain and shortening circulatory delay. Notably, these mechanisms differ between patients and between sexes, with airway collapsibility explaining a larger share of obesity-related risk in men than in women. Patients whose apnea is predominantly anatomical are the most likely to benefit from weight loss, while those driven by non-anatomical traits such as a low arousal threshold may respond more modestly.

The treatment landscape has been transformed by incretin-based therapies. The SURMOUNT-OSA trial showed that tirzepatide, a dual GIP/GLP-1 receptor agonist, produced clinically and statistically significant reductions in the apnea–hypopnea index compared with placebo, both in patients using CPAP and in those not using it, along with improvements in blood pressure, inflammatory markers, hypoxic burden and body weight. These results led to FDA approval of tirzepatide for moderate to severe OSA in people with obesity. Yet important questions remain: how well the drug performs outside tightly controlled trial settings, whether benefits are unique to tirzepatide or simply proportional to weight loss achieved, how to sequence or combine drug therapy with CPAP, and whether patients excluded from the trial—such as those with diabetes or mild apnea—would benefit similarly.

Traditional therapies remain foundational, and each has its own complexities. CPAP, the first-line treatment for many patients, is paradoxically associated with small but significant weight gain; proposed explanations include increased fat-free mass or fluid retention, hormonal changes tied to deeper slow-wave sleep, reduced respiratory work lowering caloric expenditure, and simply the return of social life—including dinners and drinks. Exercise, meanwhile, improves OSA severity by 5.2 to 8.9 events per hour in meta-analyses even without changes in BMI, possibly by activating upper airway muscles alongside the diaphragm, and it strongly predicts long-term weight maintenance. A further concern with pharmacologic weight loss is lean mass: phase 3 trials suggest roughly 20 to 40 percent of weight lost on incretin drugs comes from muscle, and resistance training with adequate protein currently offers the best protection, with muscle-preserving drugs such as bimagrumab under investigation.

At the severe end of the spectrum lies obesity hypoventilation syndrome, in which obesity combined with sleep-disordered breathing produces daytime carbon dioxide retention. OHS affects an estimated 10 to 17 percent of OSA patients, rising to as much as 50 percent in those with a BMI above 50 kg/m², and carries worse outcomes including mortality, heart failure and pulmonary hypertension. One leading mechanism is leptin resistance: leptin normally stimulates ventilation and maintains upper airway patency during sleep, but in OHS the brain’s response to the hormone is blunted. The American Thoracic Society conditionally recommends sustained weight loss of 25 to 30 percent of body weight—a target historically achievable only with bariatric surgery, though newer medications may bring it within reach non-surgically.

The review closes with a call to action that reaches beyond the clinic. Sleep disorders and obesity cluster in the same disadvantaged populations that are least likely to access new therapies, raising equity concerns as expensive drugs become central to care. The authors argue that the era of prescribing CPAP without addressing the underlying obesity should be over, that sleep deserves its place in public health messaging—the American Heart Association has already added it to its Essential Eight—and that integrated, multidisciplinary treatment models are needed. Just as managing obesity is becoming central to sleep medicine, promoting adequate sleep should be considered an essential component of weight management and overall health.

Subject of Research: Bidirectional interactions between sleep disorders and obesity

Article Title: Sleep and obesity—known interactions and open questions

Article References: Schmickl, C. N., Gomez, R., Sunwoo, B. Y., Mesarwi, O., Kumar, A. J., & Malhotra, A. (2026). Sleep and obesity—known interactions and open questions. Journal of Clinical Sleep Medicine, 22(1), Article 133. https://doi.org/10.1007/s44470-026-00130-7

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00130-7

Keywords: sleep, obesity, obstructive sleep apnea, insomnia, tirzepatide, GLP-1 receptor agonists, leptin, ghrelin, obesity hypoventilation syndrome, CPAP, weight loss, sleep deprivation